
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Paris - Topical 1 percent ciclopiroxolamine cream is a safe and effective treatment for mild-to-moderate facial seborrheic dermatitis, according to research presented at the World Congress of Dermatology.






